MAP2K7 and urothelial carcinoma: We report a unique clinical case where anti-BRAF/MEK therapy for BRAF-V600E-positive MM appeared to coincide with the emergence and progression of urothelial carcinoma, suggesting potential implications for these agents in bladder tumorigenesis.